Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 219 clinical trials
RJ_StudyVirtualF  

Acne

Online studies
  • 0 views
  • 19 Feb, 2024
  • 1 location
  • Online study
A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707)  

Primary Objectives:Evaluate the safety and tolerability of THOR-707 as a single agent and as a combination therapy (identify Dose Limiting Toxcitiy (DLTs) in Cohorts A, B, C, D, and G, and adverse events (AEs)/serious adverse event (SAE) profile in Cohorts A, B, C, D, E, F, and G)Define the Maximium …

  • 0 views
  • 04 Apr, 2025
  • 1 location
  • Online study
UAT_Local 01-19-May  

This is for UAT_Local 01-19-May.

Online studies
Accepts healthy volunteers
  • 0 views
  • 19 May, 2025
  • 1 location
  • Online study
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

The purpose of this study is to demonstrate superiority of macitentan 75 milligrams (mg) in prolonging the time to the first clinical events committee (CEC)-adjudicated morbidity or mortality (M/M) event in participants with symptomatic pulmonary arterial hypertension (PAH) compared to macitentan 10 mg.

macitentan
ventricular septal defects
ventricular septal defect
patent ductus arteriosus
connective tissue disease
  • 0 views
  • 19 Feb, 2024
  • 211 locations
Moisturizer Containing Licochalcone A, Decanediol, L-carnitine and Salicylic Acid in Reducing Relapsing of Acne  

Moisturizer containing the active ingredients of licochalcone A, decanediol, L-carnitine, and salicylic acid may be beneficial in alternative treatment of acne in maintenance phase. This study aims to evaluate the efficacy and safety of moisturizer containing the active ingredients of licochalcone A, decanediol, L-carnitine, and salicylic acid during the maintenance …

  • 0 views
  • 21 Mar, 2025
  • 2 locations
Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico  

Primary Objective: To describe the antibody titers to the antigens (meningococcal serogroups A, C, Y, and present in MenACYW conjugate vaccine or Menveo® measured by serum bactericidal assay using human complement (hSBA), for Groups 1 and 2 when administered concomitantly with routine pediatric vaccines in healthy infants and toddlers in …

Accepts healthy volunteers
  • 0 views
  • 19 Feb, 2024
  • 11 locations
Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom  

The primary objective of the study is to demonstrate the non-inferiority of the antibody responses to meningococcal serogroups A, C, W, and Y in terms of hSBA vaccine seroprotection (antibody titer ≥ 1:8) when MenACYW conjugate vaccine is administered concomitantly with Bexsero® in the second year of life compared to …

Accepts healthy volunteers
  • 0 views
  • 19 Feb, 2024
  • 12 locations
Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression

This is a randomized, double-blind, placebo-controlled, multicenter, Phase 3 study to evaluate if high-dose Octagam 10% therapy can stabilize or improve clinical status in patients with severe Coronavirus disease

pao2/fio2 ratio
pao2
chest imaging
FIO2
coronavirus infection
  • 0 views
  • 19 Feb, 2024
  • 5 locations
Carotid Doppler and EEOT for Fluid Responsiveness Prediction

Fluid responsiveness prediction prior to fluid challenge administration is a topic of interest, which has been extensively investigated, but remains challenging. In clinical practice, functional hemodynamic tests (FHT) consisting of maneuvers that affect cardiac function and/or heart-lung interaction, have been introduced in order to identify fluid responders and non-responders without …

stroke
  • 0 views
  • 19 Feb, 2024
  • 1 location
Effects of Tolperisone on Measures of Drowsiness and Cognitive Function

A Randomized, 4-Period, Crossover Study to characterize the effects of tolperisone 200 mg and 400 mg (supratherapeutic dose) three times a day (TID) over 3 days of dosing on measures of simulated driving performance, cognitive function and drowsiness and compared to placebo and cyclobenzaprine (single-day, residual effect, multiple-day).

  • 0 views
  • 19 Feb, 2024
  • 2 locations